A multi-etiology model of systemic degeneration in schizophrenia

Journal of Theoretical Biology

Volumn 259, Issue 2, 2009, Pages 269-279

  Rǎdulescu, Anca ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Autoimmunity; Dynamical system; Etiology; Modeling; Schizophrenia; Stress vulnerability

Indexed keywords

AUTOANTIBODY; DOPAMINE; HYDROCORTISONE;

ETIOLOGY; HORMONE; IMMUNITY; MENTAL HEALTH; MODELING; NERVOUS SYSTEM DISORDER;

ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNITY; BRAIN DYSFUNCTION; DEGENERATION; LIMBIC SYSTEM; MATHEMATICAL MODEL; NEUROPHYSIOLOGY; PRIORITY JOURNAL; REGULATORY MECHANISM; SCHIZOPHRENIA; STRESS; SYNAPSE; THEORETICAL MODEL;

AUTOIMMUNE DISEASES; DIAGNOSIS, DIFFERENTIAL; HUMANS; LIMBIC SYSTEM; MODELS, NEUROLOGICAL; MODELS, PSYCHOLOGICAL; PREFRONTAL CORTEX; SCHIZOPHRENIA; STRESS, PSYCHOLOGICAL;

EID: 67349223610     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2009.03.024     Document Type: Article

References (94)

1. Ananth H., et al. Cortical and subcortical gray matter abnormalities in schizophrenia determined through structural magnetic resonance imaging with optimized volumetric voxel-based morphometry. Am. J. Psych. 159 (2002)
2. Andreasen N., et al. Structural abnormalities in the frontal system in schizophrenia. A magnetic resonance imaging study. Arch. Gen. Psych. 43 (1986)
3. Andreasen N.C. Schizophrenia: the fundamental questions. Brain Res. Rev. 31 2-3 (2000) 106-112
4. Arthritis Research Campaign 〈http://www.arc.org.uk/news/pressreleases/awareness/deadly.asp〉. Released January 1998. Accessed 08/17/08.
5. Awouters F.H., and Lewi P.J. Forty years of antipsychotic drug research-from haloperidol to paliperidone-with Dr. Paul Janssen. Arzneimittelforschung. 57 10 (2007) 625-632
6. Ball T.M. Cortisol circadian rhythms and stress responses in infants at risk of allergic disease. Neuroimmunomodulation 13 5-6 (2006) 294-300
7. Bongioanni P. The bi- and unilateral correlations between the nervous system and the immune system. Minerva Med. 84 7-8 (1993) 365-381
8. Brady A.M., and O'Donnell P. Dopaminergic modulation of prefrontal cortical input to nucleus accumbens neurons in vivo. J. Neurosci. 24 5 (2004) 1040-1049
9. Bresnihan B., Oliver M., Williams B., and Hughes G.R. An antineuronal antibody cross-reacting with erythrocytes and lymphocytes in systemic lupus erythematosus. Arthritis Rheum. 22 4 (1979) 313-320
10. Bruce I., Turetsky M.D., et al. Memory-delineated subtypes of schizophrenia: relationship to clinical, neuroanatomical, and neurophysiological measures. Neuropsychology 16 (2002)
11. Cerqueira J.J., Mailliet F., Almeida O.F.X., Jay T.M., and Sousa N. The prefrontal cortex as a key target of the maladaptive response to stress. J. Neurosci. 27 11 (2007) 2781-2787
12. Cohen W., Roberts W.N., and Levenson J.L. Psychiatric aspects of SLE. In: Lahita R. (Ed). Systemic Lupus Erythematosis. fourth ed. (2004), Academic Press, San Diego, CA 785-825
13. Crow, T.J., 1980. Molecular pathology of schizophrenia: more than one disease process? Br. Med. J. 280 (6207), 6668.
14. DeLisi L.E., Weber R.J., and Pert C.B. Are there antibodies against brain in sera from schizophrenic patient? Review and prospectus. Biol. Psych. 20 (1985) 110-115
15. Denburg S.D., Carbotte R.M., and Denburg J.A. Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus. Arthritis Rheum. 37 9 (1994) 1311-1320
16. Diagnostic and Statistical Manual of Mental Disorders, 1994, fourth ed. (DSM-IV), American Psychiatric Association, Washington DC.
17. Edwards, J., Cambridge, J., 1998. Rheumatoid arthritis and autoimmunity: a new approach to their cause and how long term cure might be achieved 〈http://www.ucl.ac.uk/regfjxe/Arthritis.htm〉. Accessed 08/17/08.
18. Ehrnst A., Wiesel F.A., Bjerkenstedt L., Tribukait B., and Jonsson J. Failure to detect immunologic stigmata in schizophrenia. Neuropsychology 8 (1982) 169-171
19. Ely, L.K., Burrows, S.R., Purcell, A.W., Rossjohn, J., McCluskey, J., 2008. T-cells behaving badly: structural insights into alloreactivity and autoimmunity. Curr. Opin. Immunol. Epub.
20. Fessel W.J. Autoimmunity and mental illness. Arch. Gen. Psych. 6 (1962) 320-323
21. Finlay J.M., and Zigmond M.J. The effects of stress on central dopaminergic neurons: possible clinical implications. Neurochem. Res. 22 11 (1997) 1387-1394
22. Floresco S.B., Todd C.L., and Grace A.A. Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons. J. Neurosci. 21 13 (2001) 4915-4922
23. Ganguli R., Rabin B.S., Kelly R.H., Lyte M., and Ragu U. Clinical and laboratory evidence of autoimmunity in acute schizophrenia. Ann. N. Y. Acad. Sci. 496 (1987) 676-685
24. Gaughran, F., Welch, J., 2007. In: Lajtha, A., Galoyan A., Besedovsky, H.O. (Eds.), Handbook of Neurochemistry and Molecular Neurobiology: Neuroimmunology. 3rd edn., Springer.
25. Gharavi A.E. Anticardiolipin syndrome: antiphospholipid syndrome. Clin. Med. 1 (2001) 14-17
26. Guckenheimer J., and Holmes P. Nonlinear Oscillations, Dynamical Systems, and Bifurcations of Vector Fields (1990), Springer, Berlin
27. Hafner H., Behrens S., De Vry J., and Gattaz W.F. Oestradiol enhances the vulnerability threshold for schizophrenia in women by an early effect on dopaminergic neurotransmission. Eur. Arch. Psych. Clin. Neurosci. 241 1 (2005) 65-68
28. Haidemenos A., Kontis D., Gazi A., Kallai E., Allin M., and Lucia B. Plasma homocysteine, folate and B 12 in chronic schizophrenia. Prog. Neuropsychopharmacol. Biol. Psych. 31 6 (2007) 1289-1296
29. Harte M., and O'Connor W.T. Evidence for a differential medial prefrontal dopamine D1 and D2 receptor regulation of local and ventral tegmental glutamate and GABA release: a dual probe microdialysis study in the awake rat. Brain Res. 1017 (2004) 120-129
30. Henneberg A.E., Horter S., and Ruffert S. Increased prevalence of antibrain antibodies in the sera from schizophrenic patients. Schizophr. Res. 14 1 (1994) 15-22
31. Herbert J., Goodyer I.M., Grossman A.B., Hastings M.H., de Kloet E.R., Lightman S.L., Lupien S.J., Roozendaal B., and Seckl J.R. Do corticosteroids damage the brain?. J. Neuroendocrinol. 18 (2006) 393-411
32. Hong Y., Mager D.E., Blum R.A., and Jusko W.J. Population pharmacokinetic/pharmacodynamic modeling of systemic corticosteroid inhibition of whole blood lymphocytes: modeling interoccasion pharmacodynamic variability. Pharm. Res. 24 6 (2007) 1088-1097
33. Izhikevich E.M. Dynamical Systems in Neuroscience: The Geometry of Excitability and Bursting (2006), MIT Press, Cambridge, MA
34. Jansson L.B., and Parnas J. Competing definitions of schizophrenia: what can be learned from polydiagnostic studies?. Schizophr. Bull. 33 5 (2007) 1178-1200
35. Jovanova-Nesic K., and Shoenfeld Y. Autoimmunity in the brain: the pathogenesis insight from cell biology. Ann. N. Y. Acad. Sci. 1107 (2007) 142-154
36. Kaplan H.I., and Sadock B.J. Synopsis of Psychiatry. eighth ed. (1998), Williams & Wilkins, Baltimore, MD
37. Kapur S., and Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog. Neuropsychopharmacol. Biol. 29 5 (2005) 859-864
38. Kelly R.H., Ganguli R., and Rabin B.S. Antibody to discrete areas of the brain in normal individuals and patients with schizophrenia. Biol. Psych. 22 (1987) 1488-1491
39. Konrad, A., Winterer, G., 2007. Disturbed structural connectivity in schizophrenia primary factor in pathology or epiphenomenon? Schizophr. Bull. doi: 10.1093/schbul/sbm034.
40. Kowal C., DeGiorgio L.A., Lee J.Y., Edgar M.A., Huerta P.T., Bruce T., Volpe B.T., and Diamond B. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. PNAS 103 52 (2006) 19854-19859
41. Kiebel S.J., Kloppel S., Weiskopf N., and Friston K.J. Dynamic causal modeling: a generative model of slice timing in fMRI. Neuroimage 34 4 (2007) 1487-1496
42. Kipnis J., Cardon M., Strous R.D., and Schwartz M. Loss of autoimmune T cells correlates with brain diseases: possible implications for schizophrenia. Trends Mol. Med. 12 3 (2006) 107-112
43. Kuznetoza N.I., and Semenov S.F. Detection of antibrain antibodies in the sera of patients with neuropsychiatric disorders. Zh. Nevropatol. Psikhiatr. 61 (1961) 869-873
44. Lau C.G., and Zukin R.S. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat. Rev. Neurosci. 8 6 (2007) 413-426
45. Laviolette S.R. Dopamine modulation of emotional processing in cortical and subcortical neural circuits: evidence for a final common pathway in schizophrenia?. Schizophr. Bull. 33 4 (2007) 971-981
46. Lawrie S.M., et al. Structural and functional abnormalities of the amygdala in schizophrenia. Ann. N. Y. Acad. Sci. 985 (2003)
47. LeDoux J. The emotional brain, fear, and the amygdala. Cell Mol. Neurobiol. 23 4-5 (2003) 727-738
48. Lisman J.E., and Grace A.A. The hippocampal-VTA loop: controlling the entry of information into long-term memory. Neuron 46 (2005) 703-713
49. Lodge D.J., and Grace A.A. The hippocampus modulates dopamine neuron responsivity by regulating the intensity of phasic neuron activation. Neuropsychopharmacology 31 (2006) 1356-1361
50. Lodge D.J., and Grace A.A. Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. J. Neurosci. 27 42 (2007) 11424-11430
51. Logan D.G., and Deodhar S.D. Schizophrenia an immunologic disorder. J. Am. Med. Assoc. 212 (1970) 1703-1704
52. Medoff D.R., Holcomb H.H., Lahti A.C., and Tamminga C.A. Probing the human hippocampus using rCBF: contrasts in schizophrenia. Hippocampus 11 5 (2001) 543-550
53. Moskowitz, N., 1989. Systemic lupus erythematosus of the central nervous system: 2. Molecular theories and models for mental disease. Mt. Siani J. Med. 56 (1), 23-29.
54. Mujica-Parodi L.R., Yeregani V., et al. Nonlinear complexity and spectral analyses of heart rate variability in medicated and unmedicated patients with schizophrenia. Neuropsychobiology 51 (2005)
55. Myin-Germeys I., Delespaul P., and van Os J. Behavioural sensitization to daily life stress in psychosis. Psychol. Med. 35 5 (2005) 733-741
56. Nuechterlein K.H., et al. The vulnerability/stress model of schizophrenic relapse: a longitudinal study. Acta Psychiat. Scand. Supplementum 382 (1994)
57. Omdal R., Brokstad K., Waterloo K., Koldingsnes W., Jonsson R., and Mellgren S.I. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur. J. Neurol. 12 5 (2005) 392-398
58. Ozcan O., Ipcioglu O.M., Gultepe M., and Basogglu C. Altered red cell membrane compositions related to functional vitamin B(12) deficiency manifested by elevated urine methylmalonic acid concentrations in patients with schizophrenia. Ann. Clin. Biochem. 45 Pt 1 (2008) 44-49
59. Paulus M.P., and Braff D.L. Chaos and schizophrenia: does the method fit the madness?. Biol. Psych. 53 (2003) 3-11
60. Pavlides C., Nivon L., and McEwen B. Effects of chronic stress on hippocampal long-term potentiation. Hippocampus 12 2 (2002) 245-257
61. Peled A. Brain profiling and clinical-neuroscience. Med. Hyp. 67 4 (2006) 941-946
62. Preston A.R. Hippocampal function, declarative memory, and schizophrenia: anatomic and functional neuroimaging considerations. Curr. Neurol. Neurosci. Rep. 5 4 (2005) 249-256
63. Rǎdulescu A. Schizophrenia-a parameters' game?. J. Theor. Biol. 254 1 (2008) 89-98
64. Ritsner M., et al. Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients. Eur. Neuropsychopharmacol. 14 (2004)
65. Rosenstein M.T., Collins J.J., and De Luca C.J. A practical method for calculating largest Lyapunov exponents from small data sets. Physica D 65 1-2 (1993) 117-134
66. Rothermundt M., Arolt V., and Bayer T.A. Review of immunological and immunopathological findings in schizophrenia. Brain Behav. Immun. 15 (2001) 319-339
67. Rubin R.T. Investigation of precipitins to human brain in sera of psychotic patients. Br. J. Psych. 111 (1965) 1003-1106
68. Sajdyk T.J., and Shekhar A. Sodium lactate elicits anxiety in rats after repeated GABA receptor blockade in the basolateral amygdala. Eur. J. Pharmacol. 394 2-3 (2000) 265-273
69. Sanders S.K., and Shekhar A. Blockade of GABAA receptors in the region of the anterior basolateral amygdala of rats elicits increases in heart rate and blood pressure. Brain Res. 567 1 (1991) 101-110
70. Sanna G., Bertolaccini M.L., and Khamashta M.A. Neuropsychiatric involvement in systemic lupus erythematosus: current therapeutic approach. Curr. Pharm. Des. 14 13 (2008) 1261-1269
71. Sapolsky R.M., and Plotsky P.M. Hypercortisolism and its possible neural bases. Biol. Psych. 27 9 (1990) 937-952
72. Scolding N.J., and Joseph F.G. The neuropathology and pathogenesis of systemic lupus erithematosus. Neuropathol. Appl. Neurobiol. 28 (2002) 173-189
73. Seamans J.K., Gorelova N., Durstewitz D., and Yang C.R. Bidirectional dopamine modulation of GABAergic inhibition in prefrontal cortical pyramidal neurons. J. Neurosci. 21 10 (2001) 3628-3638
74. Seidman L.J., and Wencel H.E. Genetically mediated brain abnormalities in schizophrenia. Curr. Psych. Rep. 5 2 (2007) 135-144
75. Shanahan J.C., and Kimberly R.P. Corticosteroid use in SLE. In: Lahita R. (Ed). Systemic Lupus Erythematosis. fourth ed. (2004), Academic Press, San Diego, CA 785-825
76. Sotres-Bayon F., Bush D., and LeDoux J.E. Emotional perseveration: an update on prefrontal-amygdala interactions in fear extinction. Learn. Mem. 11 (2004) 525-535
77. Staal W.G., et al. Structural brain abnormalities in chronic schizophrenia at the extremes of the outcome spectrum. Am. J. Psych. 15 (2001)
78. Stamm R., and Buhler K.E. Concepts of vulnerability of psychiatric diseases. Fortschr. Neurol. Psychiatr. 69 7 (2001) 300-309
79. Stevenson C.W., and Gratton A. Basolateral amygdala modulation of the nucleus accumbens dopamine response to stress: role of the medial prefrontal cortex. Eur. J. Neurosci. 17 (2003) 1287-1295
80. Stojanovich L., Zandman-Goddard G., Pavlovich S., and Sikanich N. Psychiatric manifestations in systemic lupus erythematosus. Autoimmun. Rev. 6 6 (2007) 421-426
81. Strange P.G. Antipsychotic drug action: antagonism, inverse agonism or partial agonism. Trends Pharmacol. Sci. 29 6 (2008) 314-321
82. Tamminga C.A. The neurobiology of cognition in schizophrenia. J. Clin. Psych. 67 Suppl 9 (2006) 9-13 (Discussion 36-42)
83. Tanaka S. Dysfunctional GABAergic inhibition in the prefrontal cortex leading to "psychotic" hyperactivation. BMC Neurosci. 9 41 (2008)
84. Valesini G., Alessandri C., Celestino D., and Conti F. Anti-endothelial antibodies and neuropsychiatric systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 1069 (2006) 118-128
85. Volk D.W., and Lewis D.A. Impaired prefrontal inhibition in schizophrenia: relevance for cognitive dysfunction. Physiology and Behavior 77 4 (2002) 501-505
86. Walker E., Mittal V., and Tessner K. Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Ann. Rev. Clin. Psychol. 4 (2008) 189-216
87. Weinberger D., and McClure R. Neurotoxicity, neuroplasticity and magnetic resonance imaging morphometry. Arch. Gen. Psych. 59 (2002) 553-558
88. Westerink B.H.C., Enrico P., Feimann J., and de Vries J.B. The pharmacology of mesocortical dopamine neurons: a dual-probe microdialysis study in the ventral tegmental area and prefrontal cortex of the rat brain. J. Pharmacol. Exper. Therap. 285 1 (1998) 143-154
89. Williams Jr. C.A., and Schupf N. Antigen-antibody reactions in rat brain sites induce transient changes in drinking behavior. Science 196 4287 (1977) 328-330
90. Williams L.M., Harris A.W.F., Liddell B.B., Olivieri G., Phillips M.L., Peduto A., and Gordon E. Dysregulation of arousal and amygdala-prefrontal systems in paranoid schizophrenia. Amer. J. Psych. 161 3 (2004) 480-489
91. Wong E.Y.H., and Herbert J. Roles of mineralocorticoid and glucocorticoid receptors in the regulation of progenitor proliferation in the adult hippocampus. Eur. J. Neurosci. 22 (2005) 785-792
92. Yang Z.W., Chengappa N.R., Shurin G., Brar J.S., Rabin B.S., Gubbi A.V., and Ganguli R. An association between anti-hippocampal antibody concentration and lymphocyte production of IL-2 in patients with schizophrenia. Psychol. Med. 24 (1994) 449-455
93. Zhang X.Y., Zhou D.F., Cao L.Y., Wu G.Y., and Shen Y.C. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology 30 (2005) 1532-1538
94. Zhang Y., Behrens M., and Lisman J.E. Prolonged exposure to NMDAR antagonist suppresses inhibitory synaptic transmission in prefrontal cortex. J. Neurophysiol. 100 (2008) 959-965